Saturday, September 5, 2015

Human Genome Sciences again says no to GSK, exploring options

Human Genome Sciences said Thursday that its board of directors again rejected the $2.6 billion takeover offer from GlaxoSmithKline and it is talking to other pharmaceutical companies.

Human Genome Sciences again says no to GSK, exploring options


Human Genome Sciences said Thursday that its board of directors again rejected the $2.6 billion takeover offer from GlaxoSmithKline.

The two companies have partnerships linking three of HGS's most-promising drugs, which might deter other potential bidders.

Still, HGS says the $13 per share offer is insufficient and urged shareholders not to sell shares to GSK.

GSK is based in London, but has a big Center City presence and facilities in suburban Philadelphia.

More coverage

GSK had sought to takeover HGS in a friendly way, but after the first rejection, announced that it was going directly to shareholders.

“Our board of directors has concluded unanimously that the GSK offer is inadequate and does not reflect the value inherent in Human Genome Sciences,” HGS President and Chief Executive Officer H. Thomas Watkins said in a statement.

HGS said GSK was trying to take advantage of HGS's lower stock price in recent months and that talks have begun with other pharmaceutical companies.

"As part of this process, the company’s management, with the assistance of the company’s financial advisors, has engaged in discussions with a number of other parties, including major pharmaceutical and biotechnology companies, regarding a potential transaction, has entered into confidentiality agreements with certain parties and is providing those parties an opportunity to engage in a due diligence review of confidential information," the HGS statement said, without specifying which companies.

Thus far Thursday, GSK has not commented.

The HGS stock opened at $14.25 on Thursday. It's 52-week high was $28.38.

The bid for Human Genome Sciences is just the largest of a few recent moves by GSK to enlarge the empire.

The other day GSK said it completed acquisition of 10 million shares of Theravance common stock.

Earlier in the week, GSK said it spent about $98 million for the shares it didn't previously own of the privately-held company Cellzome. Cellzome does work in the proteomics technology area, meaning it researches and scans proteins to define their structures.

We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell
Also on
letter icon Newsletter